Free Trial
NASDAQ:LNSR

LENSAR Q1 2025 Earnings Report

LENSAR logo
$13.56 -0.42 (-3.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$13.56 +0.00 (+0.04%)
As of 05/23/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENSAR EPS Results

Actual EPS
-$2.32
Consensus EPS
-$0.16
Beat/Miss
Missed by -$2.17
One Year Ago EPS
N/A

LENSAR Revenue Results

Actual Revenue
$11.53 million
Expected Revenue
$13.40 million
Beat/Miss
Missed by -$1.87 million
YoY Revenue Growth
N/A

LENSAR Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

LENSAR's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

LENSAR Earnings Headlines

The Secret to Finding Breakout Stocks (Free eBook Inside!)
What if you could eliminate all the uncertainty from your trading? This isn’t just a theory—it’s a game-changer. What if, in just seconds, you could pinpoint trending small cap companies? With a single alert, you’d know exactly when to move— Here’s the good news: our team specializes in uncovering hidden gems before the market catches on.
Lensar downgraded to Hold from Buy at Lake Street
Lake Street Downgrades LENSAR (LNSR)
See More LENSAR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email.

About LENSAR

LENSAR (NASDAQ:LNSR), a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

View LENSAR Profile

More Earnings Resources from MarketBeat